Monocytopoiesis was analyzed in the bone marrow of healthy individuals. Promonocytes were identified by simultaneous determination of sodium-fluoride-sensitive and resistent naphthol-AS-D-acetate esterases. DNA synthesis activity of enzyme-positive promocytes was determined by 3H-thymidine (3H-TDR) incorporation in vitro. DNA synthesis time of these cells was measured by a double labelling technique (3H-TDR in vivo, 14C-TDR in vitro) as well as by serial injections of 3H-TDR. The relative number of promonocytes in the myelogram averaged 2.9 % corresponding to a medullar promonocyte pool of about 600 × 10B cells per kilogram body weight. The promonocytes were classified into 4 groups on the basis of nucleus morphology: type I promonocytes with small lymphocyte-like nuclei (mean frequency of occurence, F = 5 %; mean 3H-TDR labelling index, LI = 7.1 %; type II promonocytes with large round or oval nuclei (F = 31%; LI = 9.7%); type III promonocytes with large, slightly folded nuclei (F = 51%; LI = 10.1%); type IV promonocytes with large, distinctly folded nuclei (F = 13%; LI = 24.9%). LI of pooled promonocytes was 12.0%. Mean DNA synthesis times of the different types of promonocytes was similar and approximated 10 h (range 6.6–13.3 h). This was true under normal conditions as well as in septicaemia.

Keywords:
Cell kinetics, DNA synthesis, Monocytopoiesis, Promonocytes
This content is only available via PDF.
© 1975 S. Karger AG, Basel
1975
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.